CClinicalTrials.gg
CompletedNCT04130945Updated Jul 1, 2020

Cost Effect of Erector Spina Plane Block

An interventional study of erector spina plane block, cost analysis in Cost Effectiveness, sponsored by Kırıkkale University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-07-01.

Sponsored by Kırıkkale University · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Use of erector spina plane (ESP) block for postoperative analgesia is continuously increasing. However, few studies have investigated intraoperative effects of ESP block. The investigators aim to study the effects of ESP block in terms of cost-effectiveness, consumption of inhalation agents and opioids in perioperative and postoperative period.

Read the detailed description

Erector spina plane (ESP) block has analgesic efficiency and its popularity is growing steadily. ESP block forms a sensorial block by local anesthetic infiltration between the musculus erector spina and facia. ESP block given to participants undergoing laparoscopic cholecystectomy for postoperative opioid analgesia resulted in a decrease of postoperative pain scores in the first 24 h. Due to increases in health expenditure, cost control is becoming more and more important. Cost-effective studies are important in healthcare economics. Inhaled anesthetics used in anesthesia departments account for about 20% of total anesthetic agents. Local anesthetic agents decrease the minimum alveolar concentration (MAC) value of inhaled agents. And also in perioperative and post operative period, the anesthetic management often need to be supported with opioid drugs. The investigators think that ESP block has analgesic effects and decreases the consumption of inhalation agents. The investigators aim to investigate the cost-effectiveness of ESP block in anesthetic applications in laparoscopic procedures.

02

Conditions studied

  • Cost Effectiveness
03

In context

Lead sponsor

Kırıkkale University is the lead sponsor of 112 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. American Society of Anesthesiologist (ASA) physical status I-II,
  2. ages 18-75 years,
  3. undergoing laparoscopic cholecystectomy

Exclusion criteria

Exclusion Criteria:

  1. Patients with cardiac, endocrinological, neurological diseases,
  2. patients with coagulation disorders
  3. allergy to local anesthetics
  4. Operations that started as laparoscopy but transitioned to open surgery for a surgical reason
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Active comparator
    group 1

    patients with erector spine plane block

    Other: erector spina plane block, cost analysis

  • No intervention
    group 2

    patients without erector spine plane block

Interventions

  • Othererector spina plane block, cost analysis

    in preopererative period, ESP block is going to utilise for postoperative analgesia for patients who undergo laparoscopic procedure and cost analysis will make after the end of 24 hour of operation

06

What researchers measure

Primary outcomes

  1. the formula of consumption of inhaled agent

    the formula which includes fresh gas flow, valume of inhaled agent vapor, sevoflurane concentration

    Time frame: 30 minute after the operation

07

Study locations

1 site
  • Kırıkkale Univercity Faculty of Medicine Hospital
    Kırıkkale, 71450, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04130945
Lead sponsor
Kırıkkale University
Responsible party
Kevser Peker (assitant professor, Kırıkkale University) — Principal investigator
First posted
Oct 18, 2019
Start date
Sep 11, 2019
Primary completion
Nov 30, 2019
Completion
Nov 30, 2019
Last update
Jul 1, 2020

Study contacts

Kevser Peker
principal investigator · Kırıkkale University Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion